Home » Stocks » ATNF

180 Life Sciences Corp. (ATNF)

Stock Price: $3.88 USD 0.39 (11.17%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $3.87 -0.01 (-0.26%) Jan 22, 7:50 PM
Market Cap 79.39M
Revenue (ttm) n/a
Net Income (ttm) -4.70M
Shares Out 5.18M
EPS (ttm) -36.61
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $3.88
Previous Close $3.49
Change ($) 0.39
Change (%) 11.17%
Day's Open 3.45
Day's Range 3.38 - 4.18
Day's Volume 3,998,304
52-Week Range 2.15 - 11.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Newsfile Corp - 1 week ago

Menlo Park, California--(Newsfile Corp. - January 11, 2021) - 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead ...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire ...

Benzinga - 2 months ago

Last week saw continued momentum in special purpose acquisition company (SPAC) mergers, as KBL Merger (NASDAQ: KBLM), Acamar Partners Acquisition Corp. (NASDAQ: ACAM), Panacea Acquisition Corp...

Other stocks mentioned: ACAM, KBLM, PANA, SMMC
GlobeNewsWire - 2 months ago

NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire ...

Benzinga - 1 year ago

KBL Merger Corp. IV (NASDAQ: KBLM) on Friday announced its acquisition of a new cannabis biotech company CannBioRx Life Sciences Corp.

About ATNF

180 Life Sciences, a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California... [Read more...]

Industry
Biotechnology
Founded
2016
Stock Exchange
NASDAQ
Ticker Symbol
ATNF
Full Company Profile

Financial Performance

Financial Statements